{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:16:23Z","timestamp":1783937783336,"version":"3.55.0"},"reference-count":137,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurosurgery Clinics of North America"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.nec.2023.02.002","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T08:59:36Z","timestamp":1681289976000},"page":"319-333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Medical Management of Meningiomas"],"prefix":"10.1016","volume":"34","author":[{"given":"Mohammed A.","family":"Azab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyril","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Earl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Karsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.nec.2023.02.002_bib1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.critrevonc.2008.01.010","article-title":"Meningioma","volume":"67","author":"Marosi","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.nec.2023.02.002_bib2","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.3171\/2011.2.FOCUS1116","article-title":"The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments","volume":"30","author":"Choy","year":"2011","journal-title":"Neurosurg Focus"},{"issue":"6","key":"10.1016\/j.nec.2023.02.002_bib3","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/cncr.33918","article-title":"Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system","volume":"128","author":"Gritsch","year":"2022","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.nec.2023.02.002_bib5","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.wneu.2014.12.037","article-title":"The role of adjuvant radiotherapy after gross total resection of atypical meningiomas","volume":"83","author":"Hasan","year":"2015","journal-title":"World Neurosurg"},{"issue":"3","key":"10.1016\/j.nec.2023.02.002_bib6","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.3171\/2015.1.FOCUS14757","article-title":"An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas","volume":"38","author":"Sun","year":"2015","journal-title":"Neurosurg Focus"},{"issue":"10","key":"10.1016\/j.nec.2023.02.002_bib7","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1212\/01.wnl.0000271382.62776.b7","article-title":"Recurrent meningioma: salvage therapy with long-acting somatostatin analogue","volume":"69","author":"Chamberlain","year":"2007","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.nec.2023.02.002_bib8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/neuonc\/not330","article-title":"Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review","volume":"16","author":"Kaley","year":"2014","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nou148","article-title":"Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma","volume":"17","author":"Kaley","year":"2015","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.nec.2023.02.002_bib10","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/cncr.23803","article-title":"Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas","volume":"113","author":"Chamberlain","year":"2008","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.nec.2023.02.002_bib11","first-page":"1189","article-title":"Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors","volume":"55","author":"Samoto","year":"1995","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.nec.2023.02.002_bib12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4103\/0377-4929.125286","article-title":"Vascular endothelial growth factor expression and angiogenesis in various grades and subtypes of meningioma","volume":"56","author":"Dharmalingam","year":"2013","journal-title":"Indian J Pathol Microbiol"},{"issue":"4","key":"10.1016\/j.nec.2023.02.002_bib13","first-page":"938","article-title":"Vascular endothelial growth factor, hepatocyte growth factor\/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy","volume":"46","author":"Lamszus","year":"2000","journal-title":"Neurosurgery"},{"issue":"2","key":"10.1016\/j.nec.2023.02.002_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00066-010-2184-4","article-title":"Bevacizumab as a treatment option for radiation-induced cerebral necrosis","volume":"187","author":"Matuschek","year":"2011","journal-title":"Strahlenther Onkol"},{"issue":"12","key":"10.1016\/j.nec.2023.02.002_bib15","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/annonc\/mdq634","article-title":"Bevacizumab-induced regression of anaplastic meningioma","volume":"21","author":"Puchner","year":"2010","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.nec.2023.02.002_bib16","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/annonc\/mdr012","article-title":"Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab","volume":"22","author":"Goutagny","year":"2011","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.nec.2023.02.002_bib17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jocn.2011.07.024","article-title":"Regression of a meningioma during paclitaxel and bevacizumab therapy for breast cancer","volume":"19","author":"Wilson","year":"2012","journal-title":"J\u00a0Clin Neurosci"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11060-012-0861-0","article-title":"Bevacizumab therapy for adults with recurrent\/progressive meningioma: a retrospective series","volume":"109","author":"Lou","year":"2012","journal-title":"J\u00a0Neuro Oncol"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11060-012-0886-4","article-title":"Atypical and anaplastic meningiomas treated with bevacizumab","volume":"109","author":"Nayak","year":"2012","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.nec.2023.02.002_bib20","doi-asserted-by":"crossref","unstructured":"DeBoer R., Grimm S.A., Chandler J., et al., A phase II trial of PTK-787 (PTK\/ZK) in recurrent or progressive meningiomas. J Neuro Oncol, 2008;26(15_suppl):2060.","DOI":"10.1200\/jco.2008.26.15_suppl.2060"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-014-1358-9","article-title":"A\u00a0phase II trial of PTK787\/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas","volume":"117","author":"Raizer","year":"2014","journal-title":"J\u00a0Neuro Oncol"},{"issue":"2","key":"10.1016\/j.nec.2023.02.002_bib22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10735-020-09940-2","article-title":"Influence of VEGF-A, VEGFR-1-3, and neuropilin 1-2 on progression-free: and overall survival in WHO grade II and III meningioma patients","volume":"52","author":"Bernatz","year":"2021","journal-title":"J\u00a0Mol Histol"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/neuonc\/nop017","article-title":"A\u00a0phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas","volume":"12","author":"Raizer","year":"2010","journal-title":"Neuro Oncol"},{"issue":"6","key":"10.1016\/j.nec.2023.02.002_bib24","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1215\/15228517-2009-010","article-title":"Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)","volume":"11","author":"Wen","year":"2009","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.nec.2023.02.002_bib25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-009-9948-7","article-title":"Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma","volume":"96","author":"Norden","year":"2010","journal-title":"J\u00a0Neuro Oncol"},{"issue":"5","key":"10.1016\/j.nec.2023.02.002_bib26","first-page":"840","article-title":"Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea","volume":"86","author":"Schrell","year":"1997","journal-title":"J\u00a0Neurosurg"},{"issue":"2","key":"10.1016\/j.nec.2023.02.002_bib27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1023\/A:1026770624783","article-title":"Hydroxyurea chemotherapy for unresectable or residual meningioma","volume":"49","author":"Newton","year":"2000","journal-title":"J\u00a0Neuro Oncol"},{"issue":"2","key":"10.1016\/j.nec.2023.02.002_bib28","first-page":"341","article-title":"Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma","volume":"97","author":"Mason","year":"2002","journal-title":"J\u00a0Neurosurg"},{"issue":"2","key":"10.1016\/j.nec.2023.02.002_bib29","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1054\/jocn.2001.1019","article-title":"Treatment of high risk or recurrent meningiomas with hydroxyurea","volume":"9","author":"Rosenthal","year":"2002","journal-title":"J\u00a0Clin Neurosci"},{"issue":"1\u20132","key":"10.1016\/j.nec.2023.02.002_bib30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/B:NEON.0000021827.85754.8e","article-title":"Non-resectable slow-growing meningiomas treated by hydroxyurea","volume":"67","author":"Loven","year":"2004","journal-title":"J\u00a0Neuro Oncol"},{"issue":"2","key":"10.1016\/j.nec.2023.02.002_bib31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11060-004-2337-3","article-title":"Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study","volume":"74","author":"Hahn","year":"2005","journal-title":"J\u00a0Neuro Oncol"},{"issue":"3","key":"10.1016\/j.nec.2023.02.002_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1055\/s-2006-949518","article-title":"Hydroxyurea treatment of meningiomas: a pilot study","volume":"16","author":"Weston","year":"2006","journal-title":"Skull Base"},{"issue":"3","key":"10.1016\/j.nec.2023.02.002_bib33","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s11060-011-0541-5","article-title":"Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series","volume":"104","author":"Chamberlain","year":"2011","journal-title":"J\u00a0Neuro Oncol"},{"issue":"2","key":"10.1016\/j.nec.2023.02.002_bib34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11060-011-0741-z","article-title":"Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma","volume":"107","author":"Chamberlain","year":"2012","journal-title":"J\u00a0Neuro Oncol"},{"issue":"2","key":"10.1016\/j.nec.2023.02.002_bib35","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-011-0687-1","article-title":"Phase II study of Gleevec\u00ae plus hydroxyurea (HU) in adults with progressive or recurrent meningioma","volume":"106","author":"Reardon","year":"2012","journal-title":"J\u00a0Neuro Oncol"},{"issue":"5","key":"10.1016\/j.nec.2023.02.002_bib36","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1227\/01.NEU.0000245597.46581.FB","article-title":"Calcium channel antagonists augment hydroxyurea- and ru486-induced inhibition of meningioma growth in\u00a0vivo and in\u00a0vitro","volume":"59","author":"Ragel","year":"2006","journal-title":"Neurosurgery"},{"issue":"4","key":"10.1016\/j.nec.2023.02.002_bib37","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.3171\/FOC-07\/10\/E10","article-title":"Chronic suppressive therapy with calcium channel antagonists for refractory meningiomas","volume":"23","author":"Ragel","year":"2007","journal-title":"Neurosurg Focus"},{"issue":"3","key":"10.1016\/j.nec.2023.02.002_bib38","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/00006123-200003000-00032","article-title":"Calcium channel antagonist effect on in\u00a0vitro meningioma signal transduction pathways after growth factor stimulation","volume":"46","author":"Jensen","year":"2000","journal-title":"Neurosurgery"},{"issue":"6","key":"10.1016\/j.nec.2023.02.002_bib39","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3340\/jkns.2012.52.6.517","article-title":"Long-term follow-up result of hydroxyurea chemotherapy for recurrent meningiomas","volume":"52","author":"Kim","year":"2012","journal-title":"J\u00a0Korean Neurosurg Soc"},{"key":"10.1016\/j.nec.2023.02.002_bib40","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.wneu.2015.09.060","article-title":"Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies","volume":"86","author":"Karsy","year":"2016","journal-title":"World Neurosurg"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib41","first-page":"61","article-title":"Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma","volume":"8","author":"Grunberg","year":"1990","journal-title":"J\u00a0Neuro Oncol"},{"issue":"1\u20132","key":"10.1016\/j.nec.2023.02.002_bib42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF01809555","article-title":"Hormone treatment of meningiomas: lack of response to medroxyprogesterone acetate (MPA). A pilot study of five cases","volume":"80","author":"J\u00e4\u00e4skel\u00e4inen","year":"1986","journal-title":"Acta Neurochir"},{"issue":"6","key":"10.1016\/j.nec.2023.02.002_bib43","first-page":"861","article-title":"Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone","volume":"74","author":"Grunberg","year":"1991","journal-title":"J\u00a0Neurosurg"},{"issue":"8","key":"10.1016\/j.nec.2023.02.002_bib44","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/07357900601062339","article-title":"Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma","volume":"24","author":"Grunberg","year":"2006","journal-title":"Cancer Invest"},{"issue":"10","key":"10.1016\/j.nec.2023.02.002_bib45","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00701-014-2188-4","article-title":"Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486)","volume":"156","author":"Touat","year":"2014","journal-title":"Acta Neurochir"},{"issue":"6","key":"10.1016\/j.nec.2023.02.002_bib46","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/jnnp.55.6.486","article-title":"Mifepristone (RU 486) treatment of meningiomas","volume":"55","author":"Lamberts","year":"1992","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"9","key":"10.1016\/j.nec.2023.02.002_bib47","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/sj.eye.6701370","article-title":"Mifepristone treatment in patients with surgically incurable sphenoid-ridge meningioma: a long-term follow-up","volume":"18","author":"de Keizer","year":"2004","journal-title":"Eye"},{"key":"10.1016\/j.nec.2023.02.002_bib48","doi-asserted-by":"crossref","first-page":"267831","DOI":"10.1155\/2015\/267831","article-title":"The role of mifepristone in meningiomas management: a systematic review of the literature","volume":"2015","author":"Cossu","year":"2015","journal-title":"BioMed Res Int"},{"issue":"5","key":"10.1016\/j.nec.2023.02.002_bib49","first-page":"733","article-title":"Adjuvant combined modality therapy for malignant meningiomas","volume":"84","author":"Chamberlain","year":"1996","journal-title":"J\u00a0Neurosurg"},{"issue":"7","key":"10.1016\/j.nec.2023.02.002_bib50","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1212\/01.WNL.0000118300.82017.F4","article-title":"Temozolomide for treatment-resistant recurrent meningioma","volume":"62","author":"Chamberlain","year":"2004","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.nec.2023.02.002_bib51","first-page":"455","article-title":"Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas","volume":"106","author":"Gupta","year":"2007","journal-title":"J\u00a0Neurosurg"},{"issue":"20","key":"10.1016\/j.nec.2023.02.002_bib52","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1002\/cncr.27460","article-title":"Trabectedin has promising antineoplastic activity in high-grade meningioma","volume":"118","author":"Preusser","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.nec.2023.02.002_bib53","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.suronc.2015.06.004","article-title":"In\u00a0vitro testing to a panel of potential chemotherapeutics and current concepts of chemotherapy in benign meningiomas","volume":"24","author":"Balik","year":"2015","journal-title":"Surg Oncol"},{"issue":"8646","key":"10.1016\/j.nec.2023.02.002_bib54","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0140-6736(89)92465-3","article-title":"Successful treatment of meningioma with octreotide","volume":"1","author":"R\u00fcnzi","year":"1989","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.nec.2023.02.002_bib55","first-page":"237","article-title":"Clinical use of octreotide in unresectable meningiomas. A report of three cases","volume":"37","author":"Garc\u00eda-Luna","year":"1993","journal-title":"J\u00a0Neurosurg Sci"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib56","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0303-8467(97)00110-8","article-title":"Visual improvement during octreotide therapy in a case of episellar meningioma","volume":"100","author":"Jaffrain-Rea","year":"1998","journal-title":"Clin Neurol Neurosurg"},{"issue":"5","key":"10.1016\/j.nec.2023.02.002_bib57","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/neuonc\/nor044","article-title":"Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma","volume":"13","author":"Johnson","year":"2011","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.nec.2023.02.002_bib58","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00280-014-2422-z","article-title":"Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy","volume":"73","author":"Sim\u00f3","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.nec.2023.02.002_bib59","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1212\/WNL.0000000000001153","article-title":"Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma","volume":"84","author":"Norden","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib60","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11060-015-1812-3","article-title":"Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas","volume":"124","author":"Graillon","year":"2015","journal-title":"J\u00a0Neuro Oncol"},{"issue":"8","key":"10.1016\/j.nec.2023.02.002_bib61","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.nec.2023.02.002_bib62","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/neuonc\/nov177","article-title":"A\u00a0prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma","volume":"18","author":"Aizer","year":"2016","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.nec.2023.02.002_bib63","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/neuonc\/not325","article-title":"Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype","volume":"16","author":"Domingues","year":"2014","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.nec.2023.02.002_bib64","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","article-title":"DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis","volume":"18","author":"Sahm","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.nec.2023.02.002_bib65","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/neuonc\/noz061","article-title":"DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management","volume":"21","author":"Nassiri","year":"2019","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.nec.2023.02.002_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djw320","article-title":"Durable control of metastatic AKT1-mutant WHO Grade 1 meningothelial meningioma by the AKT inhibitor, AZD5363","volume":"109","author":"Weller","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6123","key":"10.1016\/j.nec.2023.02.002_bib67","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.nec.2023.02.002_bib68","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fsurg.2016.00040","article-title":"Meningioma genomics: diagnostic, prognostic, and therapeutic applications","volume":"3","author":"Bi","year":"2016","journal-title":"Front Surg"},{"issue":"5","key":"10.1016\/j.nec.2023.02.002_bib69","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/neuonc\/noaa226","article-title":"Associations of meningioma molecular subgroup and tumor recurrence","volume":"23","author":"Youngblood","year":"2021","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.nec.2023.02.002_bib70","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/neuonc\/noab213","article-title":"A\u00a0molecularly integrated grade for meningioma","volume":"24","author":"Driver","year":"2022","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.nec.2023.02.002_bib71","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","article-title":"Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities","volume":"54","author":"Choudhury","year":"2022","journal-title":"Nat Genet"},{"issue":"37","key":"10.1016\/j.nec.2023.02.002_bib72","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.18632\/oncotarget.26941","article-title":"Comparative genomic analysis of driver mutations in matched primary and recurrent meningiomas","volume":"10","author":"Loewenstern","year":"2019","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.nec.2023.02.002_bib73","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1158\/2159-8290.CD-20-0160","article-title":"The meningioma enhancer landscape delineates novel subgroups and drives druggable dependencies","volume":"10","author":"Prager","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.nec.2023.02.002_bib74","doi-asserted-by":"crossref","first-page":"892004","DOI":"10.3389\/fonc.2022.892004","article-title":"Synthesizing molecular and immune characteristics to move beyond WHO grade in meningiomas: a focused review","volume":"12","author":"Kannapadi","year":"2022","journal-title":"Front Oncol"},{"issue":"7874","key":"10.1016\/j.nec.2023.02.002_bib75","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","article-title":"A\u00a0clinically applicable integrative molecular classification of meningiomas","volume":"597","author":"Nassiri","year":"2021","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.nec.2023.02.002_bib76","doi-asserted-by":"crossref","first-page":"14551","DOI":"10.18632\/oncotarget.7396","article-title":"Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade","volume":"7","author":"Schmidt","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib77","doi-asserted-by":"crossref","first-page":"12563","DOI":"10.1038\/s41598-020-69074-z","article-title":"Comparative clinical and genomic analysis of neurofibromatosis type 2-associated cranial and spinal meningiomas","volume":"10","author":"Pemov","year":"2020","journal-title":"Sci Rep"},{"issue":"16","key":"10.1016\/j.nec.2023.02.002_bib78","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1158\/1078-0432.CCR-10-0891","article-title":"Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status","volume":"16","author":"Goutagny","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.nec.2023.02.002_bib79","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3892\/ijo_00000457","article-title":"Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype","volume":"35","author":"F\u00e8vre-Montange","year":"2009","journal-title":"Int J Oncol"},{"issue":"43","key":"10.1016\/j.nec.2023.02.002_bib80","doi-asserted-by":"crossref","first-page":"21715","DOI":"10.1073\/pnas.1912858116","article-title":"Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors","volume":"116","author":"Patel","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.nec.2023.02.002_bib81","doi-asserted-by":"crossref","first-page":"djv377","DOI":"10.1093\/jnci\/djv377","article-title":"TERT promoter mutations and risk of recurrence in meningioma","volume":"108","author":"Sahm","year":"2016","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.nec.2023.02.002_bib82","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/neuonc\/nox018","article-title":"Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1\/2 activation and reduced time to tumor recurrence","volume":"19","author":"Yesil\u00f6z","year":"2017","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.nec.2023.02.002_bib83","first-page":"345","article-title":"SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas","volume":"19","author":"Boetto","year":"2017","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.nec.2023.02.002_bib84","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00401-020-02188-w","article-title":"CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas","volume":"140","author":"Sievers","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"6","key":"10.1016\/j.nec.2023.02.002_bib85","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2217\/imt-2016-0017","article-title":"Checkpoint inhibition in meningiomas","volume":"8","author":"Bi","year":"2016","journal-title":"Immunotherapy"},{"issue":"5","key":"10.1016\/j.nec.2023.02.002_bib86","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/neuonc\/nov316","article-title":"Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma","volume":"18","author":"Abedalthagafi","year":"2016","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.nec.2023.02.002_bib87","doi-asserted-by":"crossref","first-page":"311","DOI":"10.5414\/NP300580","article-title":"Genetic changes with prognostic value in histologically benign meningiomas","volume":"32","author":"Barbera","year":"2013","journal-title":"Clin Neuropathol"},{"issue":"4","key":"10.1016\/j.nec.2023.02.002_bib88","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1215\/15228517-2007-026","article-title":"Early recurrences in histologically benign\/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone","volume":"9","author":"Maillo","year":"2007","journal-title":"Neuro Oncol"},{"issue":"12","key":"10.1016\/j.nec.2023.02.002_bib89","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/neuonc\/noq081","article-title":"Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas","volume":"12","author":"P\u00e9rez-Mag\u00e1n","year":"2010","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.nec.2023.02.002_bib90","first-page":"341","article-title":"Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II","volume":"25","author":"Ruiz","year":"2010","journal-title":"Histol Histopathol"},{"issue":"6","key":"10.1016\/j.nec.2023.02.002_bib91","doi-asserted-by":"crossref","first-page":"e67291","DOI":"10.1371\/journal.pone.0067291","article-title":"Gene expression profiles of metabolic aggressiveness and tumor recurrence in benign meningioma","volume":"8","author":"Serna","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.nec.2023.02.002_bib92","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/bpa.12150","article-title":"Genetic profiling by single-nucleotide polymorphism-based array analysis defines three distinct subtypes of orbital meningioma","volume":"25","author":"Ho","year":"2015","journal-title":"Brain Pathol"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib93","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41467-017-00174-7","article-title":"Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas","volume":"8","author":"Agnihotri","year":"2017","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.nec.2023.02.002_bib94","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00401-019-02008-w","article-title":"Mutational patterns and regulatory networks in epigenetic subgroups of meningioma","volume":"138","author":"Paramasivam","year":"2019","journal-title":"Acta Neuropathol"},{"issue":"20","key":"10.1016\/j.nec.2023.02.002_bib95","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1038\/onc.2010.609","article-title":"Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes","volume":"30","author":"Kalamarides","year":"2011","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib96","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1038\/s41598-021-86298-9","article-title":"Associations of pathological diagnosis and genetic abnormalities in meningiomas with the embryological origins of the meninges","volume":"11","author":"Okano","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib97","first-page":"vdz011","article-title":"Integrated models incorporating radiologic and radiomic features predict meningioma grade, local failure, and overall survival","volume":"1","author":"Morin","year":"2019","journal-title":"Neurooncol Adv"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib98","first-page":"59","article-title":"Clinical and diffusion parameters may noninvasively predict TERT promoter mutation status in grade II meningiomas","volume":"49","author":"Shin","year":"2022","journal-title":"J\u00a0Neuroradiol"},{"issue":"5","key":"10.1016\/j.nec.2023.02.002_bib99","doi-asserted-by":"crossref","first-page":"eabm6247","DOI":"10.1126\/sciadv.abm6247","article-title":"Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies","volume":"8","author":"Bayley","year":"2022","journal-title":"Sci Adv"},{"issue":"8","key":"10.1016\/j.nec.2023.02.002_bib100","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/neuonc\/noaa303","article-title":"H3K27me3 loss indicates an increased risk of recurrence in the T\u00fcbingen meningioma cohort","volume":"23","author":"Behling","year":"2021","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.nec.2023.02.002_bib101","doi-asserted-by":"crossref","first-page":"e12970","DOI":"10.1111\/bpa.12970","article-title":"Prognostic impact of genetic alterations and methylation classes in meningioma","volume":"32","author":"Berghoff","year":"2022","journal-title":"Brain Pathol"},{"issue":"6","key":"10.1016\/j.nec.2023.02.002_bib102","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00401-018-1844-9","article-title":"Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence","volume":"135","author":"Katz","year":"2018","journal-title":"Acta Neuropathol"},{"issue":"34","key":"10.1016\/j.nec.2023.02.002_bib103","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.21.00784","article-title":"Integrated molecular-morphologic meningioma classification: a multicenter retrospective analysis, retrospectively and prospectively validated","volume":"39","author":"Maas","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.nec.2023.02.002_bib104","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/neuonc\/noab036","article-title":"Loss of H3K27me3 in meningiomas","volume":"23","author":"Nassiri","year":"2021","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.nec.2023.02.002_bib105","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00401-017-1678-x","article-title":"Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma","volume":"133","author":"Olar","year":"2017","journal-title":"Acta Neuropathol"},{"issue":"10","key":"10.1016\/j.nec.2023.02.002_bib106","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/NEN.0b013e31826bf704","article-title":"Genetic alterations associated with progression and recurrence in meningiomas","volume":"71","author":"P\u00e9rez-Mag\u00e1n","year":"2012","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"issue":"5","key":"10.1016\/j.nec.2023.02.002_bib107","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.ajpath.2012.07.033","article-title":"Immunophenotypic identification and characterization of tumor cells and infiltrating cell populations in meningiomas","volume":"181","author":"Domingues","year":"2012","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib108","first-page":"vdz018","article-title":"Tumor-associated macrophage infiltration in meningioma","volume":"1","author":"Proctor","year":"2019","journal-title":"Neurooncol Adv"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib109","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2990.2008.00960.x","article-title":"The microglial\/macrophagic response at the tumour-brain border of invasive meningiomas","volume":"35","author":"Grund","year":"2009","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"6","key":"10.1016\/j.nec.2023.02.002_bib110","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00262-019-02342-8","article-title":"Systemic and local immunosuppression in patients with high-grade meningiomas","volume":"68","author":"Li","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"10.1016\/j.nec.2023.02.002_bib111","doi-asserted-by":"crossref","first-page":"e1440931","DOI":"10.1080\/2162402X.2018.1440931","article-title":"Immunosuppressive activity of tumor-infiltrating myeloid cells in patients with meningioma","volume":"7","author":"Pinton","year":"2018","journal-title":"OncoImmunology"},{"issue":"2","key":"10.1016\/j.nec.2023.02.002_bib112","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11060-022-03979-9","article-title":"Immune checkpoint inhibitor therapy for recurrent meningiomas: a retrospective chart review","volume":"157","author":"Nidamanuri","year":"2022","journal-title":"J\u00a0Neuro Oncol"},{"issue":"11","key":"10.1016\/j.nec.2023.02.002_bib113","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/neuonc\/not110","article-title":"The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells","volume":"15","author":"Fang","year":"2013","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.nec.2023.02.002_bib114","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11060-018-2891-8","article-title":"Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design","volume":"139","author":"Everson","year":"2018","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.nec.2023.02.002_bib115","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3389\/fneur.2020.00945","article-title":"Basis for immunotherapy for treatment of meningiomas","volume":"11","author":"Garzon-Muvdi","year":"2020","journal-title":"Front Neurol"},{"issue":"3","key":"10.1016\/j.nec.2023.02.002_bib116","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11060-016-2256-0","article-title":"Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma","volume":"130","author":"Han","year":"2016","journal-title":"J\u00a0Neuro Oncol"},{"issue":"17","key":"10.1016\/j.nec.2023.02.002_bib117","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1158\/1078-0432.CCR-19-0389","article-title":"Cytotoxic T cells and their activation status are independent prognostic markers in meningiomas","volume":"25","author":"Rapp","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib118","doi-asserted-by":"crossref","first-page":"9065","DOI":"10.1038\/s41598-020-65365-7","article-title":"Landscape of immune cell gene expression is unique in predominantly WHO grade 1 skull base meningiomas when compared to convexity","volume":"10","author":"Zador","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.nec.2023.02.002_bib119","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jocn.2019.06.003","article-title":"Immunological and vascular characteristics in cavernous sinus meningioma","volume":"67","author":"Kosugi","year":"2019","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.nec.2023.02.002_bib120","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12974-015-0388-3","article-title":"Mast cells in meningiomas and brain inflammation","volume":"12","author":"Polyzoidis","year":"2015","journal-title":"J\u00a0Neuroinflammation"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib121","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10143-005-0402-9","article-title":"Secretory meningioma: immunohistochemical findings and evaluation of mast cell infiltration","volume":"29","author":"Tirakotai","year":"2006","journal-title":"Neurosurg Rev"},{"issue":"5","key":"10.1016\/j.nec.2023.02.002_bib122","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20200538","article-title":"Profiles of immune infiltration and its relevance to survival outcome in meningiomas","volume":"40","author":"Chen","year":"2020","journal-title":"Biosci Rep"},{"issue":"7","key":"10.1016\/j.nec.2023.02.002_bib123","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1515\/revneuro-2020-0106","article-title":"The glymphatic system and meningeal lymphatics of the brain: new understanding of brain clearance","volume":"32","author":"Yankova","year":"2021","journal-title":"Rev Neurosci"},{"issue":"7560","key":"10.1016\/j.nec.2023.02.002_bib124","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature14432","article-title":"Structural and functional features of central nervous system lymphatic vessels","volume":"523","author":"Louveau","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib125","doi-asserted-by":"crossref","first-page":"7194","DOI":"10.1038\/s41598-018-25666-4","article-title":"Magnetic resonance imaging provides evidence of glymphatic drainage from human brain to cervical lymph nodes","volume":"8","author":"Eide","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.nec.2023.02.002_bib126","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2990.2007.00926.x","article-title":"Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology","volume":"34","author":"Carare","year":"2008","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.nec.2023.02.002_bib127","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jocn.2016.11.011","article-title":"Regression of intracranial meningioma following treatment with nivolumab: Case report and review of the literature","volume":"37","author":"Gelerstein","year":"2017","journal-title":"J\u00a0Clin Neurosci"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib128","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/neuonc\/noab118","article-title":"Activity of PD-1 blockade with nivolumab among patients with recurrent atypical\/anaplastic meningioma: phase II trial results","volume":"24","author":"Bi","year":"2022","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.nec.2023.02.002_bib129","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11060-005-9093-x","article-title":"Salvage chemotherapy with CPT-11 for recurrent meningioma","volume":"78","author":"Chamberlain","year":"2006","journal-title":"J\u00a0Neuro Oncol"},{"issue":"2","key":"10.1016\/j.nec.2023.02.002_bib130","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00006123-199702000-00007","article-title":"The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B","volume":"40","author":"Kaba","year":"1997","journal-title":"Neurosurgery"},{"issue":"8","key":"10.1016\/j.nec.2023.02.002_bib131","first-page":"2269","article-title":"Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography","volume":"7","author":"Muhr","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.nec.2023.02.002_bib132","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0090-3019(85)90030-8","article-title":"Antiestrogenic therapy of meningiomas--a pilot study","volume":"24","author":"Markwalder","year":"1985","journal-title":"Surg Neurol"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib133","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01050266","article-title":"A\u00a0phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study","volume":"15","author":"Goodwin","year":"1993","journal-title":"J\u00a0Neuro Oncol"},{"issue":"3","key":"10.1016\/j.nec.2023.02.002_bib134","doi-asserted-by":"crossref","first-page":"e59941","DOI":"10.1371\/journal.pone.0059941","article-title":"Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients","volume":"8","author":"Nunes","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.nec.2023.02.002_bib135","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11060-016-2172-3","article-title":"A\u00a0phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma","volume":"129","author":"Shih","year":"2016","journal-title":"J\u00a0Neuro Oncol"},{"issue":"6","key":"10.1016\/j.nec.2023.02.002_bib136","doi-asserted-by":"crossref","first-page":"e0217340","DOI":"10.1371\/journal.pone.0217340","article-title":"Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between octreotide in combination with everolimus and sunitinib","volume":"14","author":"Cardona","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.nec.2023.02.002_bib137","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/s41467-022-29052-7","article-title":"Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas","volume":"13","author":"Brastianos","year":"2022","journal-title":"Nat Commun"}],"container-title":["Neurosurgery Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1042368023000141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1042368023000141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:04:21Z","timestamp":1760904261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1042368023000141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":137,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1042368023000141"],"URL":"https:\/\/doi.org\/10.1016\/j.nec.2023.02.002","relation":{},"ISSN":["1042-3680"],"issn-type":[{"value":"1042-3680","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Management of Meningiomas","name":"articletitle","label":"Article Title"},{"value":"Neurosurgery Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nec.2023.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}